Graduate Fellows: Publications
Home > Cancer (Oncology) > Education > Hematology Oncology Fellowship > Graduate Fellows: Publications


Fellow's Publications

Recent Graduates/Current Fellows


  1. Abdullah, S. E. and Perez-Soler, R. (2011), Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer. 2012; 118:3455-67. PMID: 22086782.

  2. Reed LR, Raghupathy R,  Strakhan M, Philbeck TE, Kim MY,  Battini B,  Hussain Z, Abdullah S, Schweber S, Bala K. Pacello T. The OnControl bone marrow biopsy technique is superior to the standard manual technique for hematologists-in-training: a prospective, randomized comparison.  Hematology Reports 2011; 3:e21. PMID: 22593813.

  3. Janakiram M, Thirukonda VK, Sullivan M, Petrich AM. Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma. Curr Treat Options Oncol 2012; 13: 82-101. PMID: 22297843.

  4. Giricz O, Reynolds PA, Ramnauth A, Liu C, Wang T, Stead L, Childs G, Rohan T, Shapiro N, Fineberg S, Kenny PA, Loudig O. Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity.  J Pathol. 2012; 226:108-19. PMID: 21953071.

  5. Ayyappan S, Janakiram M, Raghupathy R. Current and emerging therapies in primary myelofibrosis. Cardiovasc Hematol Disord Drug Targets 2012; 12:6-20. PMID: 22746348.

  6. Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012; 120:386-94. PMID: 22627766.

  7. Abdullah SE, Haigentz M Jr, Piperdi B. Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management. Chemother Res Pract  2012; 2012:351210 PMID: 22997576.

  8. Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A, Verma A. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.Int J Clin Exp Pathol. 2012; 5:382-96. PMID: 22808291.

  9. Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat TD, Bhattacharyya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 2012; 120:2076-86. PMID: 22753872.

  10. Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, Gordon S, Fazzari MJ, Ye BH, Sparano JA, Parekh S. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Clin Cancer Res. 2012; 18:2534-44. PMID: 22338016.

  11. Janakiram M, Abadi YM, Sparano JA, Zang X. T cell coinhibition and immunotherapy in human breast cancer. Discov Med. 2012; 14:229-36. PMID: 23114578. 

  12. Bayraktar UD, Ramos JC, Petrich A, Gupta N, Lensing S, Moore PC, Reid EG, Aboulafia DM, Ratner L, Mitsuyasu R, Cooley T, Henry DH, Barr P, Noy A.Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. Leuk Lymphoma. 2012; 53:2383-9. PMID: 22642936.

  13. Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012; 12; 120:386-94. PMID: 22627766.

  14. Petrich AM, Sparano JA, Parekh S. Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma. Adv Hematol. 2012; 10:765-6. PMID: 23271267.

  15. Thirukonda V, Petrich A, Parekh S. Classical Hodgkin lymphoma and spontaneous regression. Clin Adv Hematol Oncol. 2012; 10:765-6. PMID: 23271267.

  16. Wang Y, Sparano JA, Fineberg S, Stead L, Sunkara J, Horwitz SB, McDaid HM. High Expression of Class III β-Tubulin Predicts Good Response to Neoadjuvant Taxane and Doxorubicin/Cyclophosphamide-Based Chemotherapy in Estrogen Receptor-Negative Breast Cancer. Clin Breast Cancer. 2013; 13:103-8. PMID: 23218766.

  17. Diaz J, Stead L, Shapiro N, Newell R, Loudig O, Lo Y, Sparano J, Fineberg S.  Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease. Breast Cancer Res Treat. 2013; 138:91-7. PMID: 23417359.

  18. Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, Tamari R, Gordon S, Mantzaris I, Jodlowski T, Yu Y, Jing X, Polineni R, Bhatia K, Pellagatti A, Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. Blood. 2013; 121:2875-81. PMID: 23390194.

  19. Pathak S, Roth M, Verma A, Steidl U. Eltrombopag for the Treatment of Thrombocytopenia in Patients with Malignant and Non-Malignant Hematologic Disorders.Expert Opin Drug Metab Toxicol. 2013; 9:667-1675. PMID: 24215532.

  20. Janakiram M, Sullivan M, Shcherba M, Guo S, Billett HH. A systematic review of the utility of residual vein obstruction studies in primary and secondary venous thrombosis. Thrombosis. 2013; 2013:247913. doi: 10.1155/2013/247913. Epub 2013 Nov 19. PMID: 24349773.

  21. Janakiram M, Assal A, Sparano J. TAILORx: A trial design towards our goal of personalized medicine. Personalized Medicine in Oncology. Personalized Medicine in Oncology. 2013 Dec; 2(8): 452-6.  PMID: 254400090.

  22. Shcherba M, Shuter J, Haigentz M Jr. Current questions in HIV-associated lung   cancer. Curr Opin Oncol. 2013; 25:511-517. PMID: 23942294.

  23. Khan H, Vale C, Bhagat T, Verma A. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Semin Hematol. 2013; 50: 16-37. PMID: 23507481.

  24. Dai T, Friedman EW, Barta SK. Ruxolitinib withdrawal syndrome leading to tumor lysis. J Clin Oncol. 2013; 31: e430-2. PMID: 23752116.

  25. Lam AP, Gundabolu K, Sridharan A, Jain R, Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S, Verma AK. Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia. Am J Hematol. 2013; 88:E245-9. PMID: 23828763.

  26. Piperdi B, Merla A, Perez-Soler R. Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer. Drugs. 2014; 74: 403-13 PMID:24578213.

  27. Msaouel P, Lam AP, Gundabolu K, Chrysofakis G, Yu Y, Mantzaris I, Friedman E, Verma A. Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity. Haematologica. 2014; 9:930-6. PMID: 24510340.

  28. Shcherba M, Liang Y, Fernandes D, Perez-Soler R, Cheng H. Cell cycle inhibitors for the treatment of NSCLC. Expert Opin Pharmacother. 2014; 15:991-1004. PMID: 24666387.

  29. Ng C, Schwartzman L, Moadel R, Haigentz M Jr. Osteopoikilosis: A Benign Condition with the Appearance of Metastatic Bone Disease. J Clin Oncol. 2014; PMID: 24663043.

  30. Tamari R, Schinke C, Bhagat T, Roth M, Braunschweig I, Will B, Steidl U, Verma A. Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone. Leuk Lymphoma. 2014; 55:2901-6. PMID: 24650011.

  31. Pondt C, Rajdev L. Neoadjuvant and Adjuvant Therapy for Gastrointestinal Tumors. J Gastroint Dig Syst 2014, 4:2.

  32. Bachegowda LS, Barta SK. Genetic and molecular targets in lymphoma: implications for prognosis and treatment. Future Oncol. 2014; 10 15:2509-28. PMID: 25525858.

  33. Cheng H, Shcherba M, Pendurti G, Liang Y, Piperdi B, Perez-Soler R. Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment.  Lung Cancer Manag. 2014 3:67-75. PMID: 25342981. 

  34. Konda B, Pathak S, Edwin I, Mishall P, Downie SA, Olson TR, Reed LJ, Friedman EW.   Safe and successful bone marrow biopsy: an anatomical and CT-based cadaver study. Am J Hematol. 2014; 89:943-6. PMID: 24942104.

  35. Shastri A, Shastri SS.Cancer screening and prevention in low-resource settings. Nat Rev Cancer. 2014;14:822-9. PMID: 25355377.

  36. Shcherba M, Liang Y, Fernandes D, Perez-Soler R, Cheng H. Cell cycle inhibitors for the treatment of NSCLC. Expert Opin Pharmacother. 2014; 15:991-1004. PMID: 24666387.

  37. Bachegowda LS, Makower DF, Sparano JA. Taxanes: impact on breast cancer therapy. Anticancer Drugs. 2014; 25:512-21.PMID: 24552749.

  38. Shum H, Rajdev L. Multimodality management of resectable gastric cancer: A review. World J Gastrointest Oncol. 2014 Oct 15; 6):393-402. PMID:25320655.

  39. Shum H, Rajdev L.  Targeted therapy in advanced gastric cancer: An updated review.  J Cancer Sci 2014; 1:1-13.

  40. Strakhan M, Hurtado-Sbordoni M, Galeas N, Bakirhan K, Alexis K, Elrafei T.  36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol. 2014 2014:704371. PMID: 25389502.

  41. Konda B, Bakirhan K, Rajdev L. Systemic treatment of colon cancer. Austin J Med Oncol.2014; 1(2):11.

  42. Chuy J, Konda B, Rajdev L. Current and Emerging Treatment Targets in AdvancedHepatocellular Carcinoma. JSM Clin Oncol Res. 2014; 2: 1039. 

  43. Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM.  Therapies for triple negative breast cancer.   Expert Opin Pharmacother. 2015; 16:1-16 PMID: 25881743.

  44. Cheng H, Shcherba M, Kandavelou K, Liang Y, Liu H, Perez-Soler R. Emerging drugs for squamous cell lung cancer. Expert Opin Emerg Drugs. 2015; 20:149-60. PMID: 25557559.

  45. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015; 21:24-33. PMID: 25440090.

  46. Augustine TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, Aparo S, Maitra R, Goel S. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. Br J Cancer. 2015: 112:313-8 PMID: 25412235.

  47. Schinke, C, Giricz O, Li W, Shastri A, Gordon S, Barreyro L, Bhagat T, Bhattacharya S, Will B, Steidl U, Verma A. IL-8/CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells, Blood, 2015; 125:3144-52. PMID: 25810490.

  48. Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Little RF, Dunleavy K, Wilson WH, Wyen C, Remick SC, Kaplan LD, Ratner L, Noy A, Sparano JA. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol. 2015; 26:958-966. PMID:25632071.

Abstracts and Posters

  1. Janakiram M, Sullivan, MR, Shcherba M, Guo, M. and Billett, HH. Residual Vein Residual Vein Obstruction (RVO) Predicts Recurrence for Cancer Patients with Secondary VTE: A Meta-Analysis.  ASH Annual Meeting Abstracts, Blood 2012; 120: 2259.

  2. SK. Barta, X Xue, R Tamari, JY Lee, NM, Lawrence D. Kaplan, J-M Ribera, M Spina, R Weiss, L Galicier, F Boue, WH Wilson, C Wyen, JT Navarro, K Dunleavy, RF Little, L  Ratner, M Morgades, O Garcia, JA Sparano; A pooled analysis of 1144 patiennts wit HIV associated lymphoma: Assesment  of lymphoma, HIV, and treatment spesific factors on clinical outcomes. ASCO Annual Meeting abstracts, J Clin Oncol 2012; 30: (suppl; abstr 8005).
  4. MA Baig, A Merla, TA Augustine,  G Atzmon, T Budagov, S Goel, R Maitra. Association of telomere length (TL) with clinical outcomes in patients with colorectal carcinoma (CRC). ASCO Annual Meeting abstracts, J Clin Oncol 2012; (suppl 34; abstr 418)

  5. M. Shcherba, S Viswanathan, D Blakaj, M Garg, M Haigentz. Treatment-associated mortality in head and neck cancer: Analysis of phase III trials. ASCO Annual Meeting abstracts, J Clin Oncol 31, 2013 (suppl; abstr 6064).

  6. S. Schweber, AG. Rodriguez-LaRocca, V. Calvert, E. Petricoin, SB. Horwitz, E. Andreopoulou, HM. McDaid. Protein pathway activation mapping guided biomarker development to identify optimal combinations of MEK inhibitor with PI3K/mTOR pathway inhibitors for the treatment of triple-negative breast cancer. ASCO Annual Meeting abstracts, J Clin Oncol 31, 2013 (suppl; abstr 2612).

  7. U. Shah, G. Pendurti, U. Swami, Y. Hou, MH. Ghalib, I. Chaudhary, S. Mani, S. Goel, S. Aparo. Clinical outcome for patients with metastatic colorectal cancer (mCRC) enrolled in phase I clinical trials: Single institution experience. ASCO Annual Meeting abstracts,J Clin Oncol  2013; 31: (suppl; abstr e13550).

  8. E. Andreopoulou, IS. Vigoda, V. Valero, DL. Hershman, G. Raptis, LT. Vahdat, HS. Han, JJ. Wright, CM. Pellegrino, RH. Alvarez, K. Fehn, S. Fineberg, JA. Sparano; A phase I-II study of tipifarnib plus weekly paclitaxel (P) followed by dose-dense doxorubicin/cyclophosphamide (AC) in stage IIb-IIIc breast cancer (BC). ASCO Annual Meeting abstracts,  J Clin Oncol  2013; 31: (suppl; abstr 1118).

  9. SK. Barta, M. Samuel, X. Xue, JY. Lee, N. Mounier, LD. Kaplan, JM. Ribera, M. Spina, U. Tirelli, R. Weiss, L. Galicier, F. Boue, WH. Wilson, C. Wyen, K. Dunleavy, RF. Little, SC. Remick, M. Goldfinger, A. Noy, J A. Sparano: A pooled analysis of 1,546 patients with AIDS-related lymphoma (ARL): An assessment of prognostic factors by treatment era. ASCO Annual Meeting Abstracts,  J Clin Oncol  2013; 31: (suppl; abstr 8524).

  10. Kalinsky K, Andreopoulou E, Tu Y, Sparano J, et al. Ethnic difference in tumor proliferation in women with early-stage breast cancer. American Society of Clinical Oncology (ASCO) 2013 annual meeting. Abstract # 560

  11. MA. Baig, TA. Augustine, A. Merla, G. Atzmon, T. Budagov, S. Goel, R. Maitra; Association of telomere length with clinical outcomes in patients with colorectal carcinoma. ASCO Annual Meeting Abstracts, J Clin Oncol  2013; 31: (suppl; abstr e14540).

  12. S Pathak, B Konda, I Edwin, Priti L. Mishall, SA. Downie, TR. Olson, LJ. Reed, EW. Friedman. Accurate Needle Placement - A Must For a Safe and Effective Bone Marrow Biopsy Procedure: An Anatomical and CT Based Cadaver Study.  ASH Annual Meeting Abstracts,  Blood 2013 122:1752.

  13. K Gundabolu, H Chen, H Li, L Shakaladevanapura, TD. Bhagat, N Vallumsetla, Y Ginzburg, A Verma. Inhibition Of Erythropoiesis By Iron Overload Is Mediated Through TGFβ Signaling. ASH Annual Meeting Abstracts Blood 2013; 122:2787.

  14. A Sridharan, R Jain, M Bachhuber, AP. Lam, Y Yu, EW. Friedman, A Verma. Anisocytosis Is Associated With Decreased Survival In Patients With Newly Diagnosed Myelodysplastic Syndromes: A Single Center Experience. ASH Annual Meeting Abstracts, Blood 2013; 122:5218.

  15. A Sharma, LV Vasovic, X Xue, D Wang, I Braunschweig, SK Barta. A Higher Number Of CD34+ Cells Collected During Mobilization Is Independently Associated With Successful Engraftment In Autologous Stem Cell Transplant Patients.  ASH Annual Meeting Abstracts, Blood 2013; 122:5442.

  16. E Jou, O Gligich, ACY Chan, D Mohan, F Uri, HH Billett, ATC Chan, R Raghupathy. The Incidence and Risk Factors For Hematological Malignancies and Premalignant Hematological Disorders In HIV. ASH Annual Meeting Abstracts, Blood 2013; 122:4304.

  17. M Shcherba, HD Hosgood, J Lin, D Hanna, UR. Felsen, M Ginsberg, L Fisher, K Wilson, Chung, X Xue, K Anastos, B Piperdi, S Spivack, SM. Keller, HD. Strickler, M Haigentz. Characteristics of HIV+ lung cancer cases in a large clinical population: Implications for lung cancer screening. 2014 ASCO Annual Meeting. Abstract, No:1569.

  18. C Inal, E Yilmaz, H Cheng, C Zhu, J Pullman, RA. Gucalp, SM. Keller, R Perez-Soler, B Piperdi. Effect of reflex testing by pathologists on molecular testing rates in lung cancer patients: Experience from a community-based academic center. 2014 ASCO Annual Meeting. Abstract No: 8098

  19. Tu Y, DL Hershman, CM. Pellegrino, E Andreopoulou, D Makower, S Fineberg, KN.Bhalla, K Kalinsky, K Fehn, M Huang, RK Alpaugh, JA Sparano. Phase I-II study of the histone deacetytase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. 2014 ASCO Annual Meeting, Abstract No: 598.

  20. UH  Shah, AA Khot, D Goyal, S Guo, A Kaubisch, L  Rajdev, S  Goel, S  Aparo. A model of comparative effectiveness research (CER): The impact of biologic agents in a cohort of patients from ethnic minorities with metastatic colorectal cancer (mCRC). 2014 ASCO Annual Meeting Abstract No:e14503.

  21. J Joshi, N  Mounier, X  Xue, D Wang, JM Ribera, C  Wyen, K  Dunleavy, RF Little, WH Wilson, A Noy, JoA Sparano, SK Barta. CNS involvement in patients with AIDS-related lymphomas. 2014 ASCO Annual Meeting Abstract No:8570.

  22. A Sridharan, SA Curtis, JD Kaner, S Aparo, SK. Barta. Hepatitis C co-infection in HIV-positive patients treated for lymphoma. 2014 ASCO Annual Meeting Abstract No:8578.

  23. Lee L, Konda B, Assal A, Zell M, Braunschweig I, Derman O, Kornblum N, Battini R, Verma A, Janakiram M. Plasmablastic lymphoma : A case series of the changing epidemiology of a rare extramedullary plasmacytoid neoplasm, diagnostic challenges and therapeutic implications. Blood 2014 124:2995;

  24. Zell M, Assal A, Konda B, Lee L, Braunschweig I, Derman O, Kornblum N, Battini R, Verma A, Janakiram M. Analysis of large cohort shows that Caribbean Adult T cell leukemia/lymphoma is a chemo refractory disease with very poor prognosis that behaves distinctly from Japanese subtypes. Blood. 2014; 124:1685:

  25. Assal A, Kaner JD, Danda N, Billett HH. Ovarian Vein Thrombosis: Clinical Features, Risk Factors, and Outcomes. Blood 2014 124:587;

  26. Assal A, Medavarapu R, Friedman EW, Yu Y, Verma A, Derman O. Outcomes and Treatment Patterns of Patients with CML in an Inner-City, Underserved, Multi-Ethnic Patient Cohort Reveals Good Overall Survival with Both First and Second Generation TKIs As Initial Therapy. Blood 2014 124:5522;

  27. Shastri A, Schinke C, Varshavsky A, VermaA et all. Targeting of MDS and AML Stem Cells via Inhibition of STAT3 By Pyrimethamine. Blood 2014 124:3602;
  29. Shastri A, Yu Y, Verma A, Barta SK. Sites of Extranodal Involvement Are Prognostic in Patients with Stage I Follicular Lymphoma: An Analysis of the Surveillance, Epidemiology and End Results Database. Blood 2014 124:1670;

  30. Rodgers C, Shastri A, Battini R. Outcome of HCV-Positive Patients with Lymphoma Treated with Rituximab Containing Therapies. Blood 2014 124:1713;

  31. Jou E, Cheung CKM,  Ho RC, Mohan D, Felsen EU, Billett HH, Chan ATC, Hui EP,  Raghupathy R. Retrospective Study of the Incidence and Risk Factors for Hematological Malignancies in Patients with Hepatitis B Virus Infection. Blood 2014 124:5403;

  32. Bachegowda LS, Mantzaris I, Morrone KA, Keshkar N, Li W, Nwankwo G, Shahnaz S, Bhagat TD, Giricz O, Bhattacharrya S, Yu Y,  Schinke CD, Pynadath A, Pellagatti A, Boultwood J, Humphries MJ, Winski SL, Bartenstein M, Guha C, Platanias L, Steidl U, Verma A. Efficacy of Dual Inhibition of p38 Mitogen Activated Protein Kinase (MAPK) and Tie-2 Kinase in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood 2014 124:4628.

  33. Mantzaris I, Msaouel P, Lam AP, Friedman EW, Yu Y, Verma A. Ethnicity Specific Cutoffs for Neutropenia Are Predictive of Overall Survival in a Large Elderly Cohort: An Analysis of 26,652 Individuals. Blood 2014 124:4944; 

  34. Bhagat TD, Bartenstein M, Yiting Yu, Marcondes AMQ, Will B, Giricz O, Sohal DP,  Mantzaris I, Wickrema A, Mcmahon C, Cecilia Y, Greally J, Mukherjee S, Steid U, Deeg HC, Verma A. Myelodysplastic Syndrome Marrow Stroma Shows Widespread Aberrant Hypermethylation That Is Abrogated By Treatment with Dnmt Inhibitors. Blood 2014 124:4379;

  35. Shaker A, Shapira I, Oswald M, Shih A, Mason C, Keogh M, Lee A MicroRNA expression in tissue and plasma of patients with benign cystic ovarian masses and ovarian cancer points to distinct molecular pathways for proliferations and metastases. Poster presentation at the Association for Clinical and Translational Science 2015 meeting, Washington, DC.

  36. Shaker A, Shapira I, Oswald M, Shih A, Mason C, Keogh M, Lee A. Plasma and tissue microRNA patterns are distinct in breast cancer patients relative to healthy controls. Poster presentation at the Association for Clinical and Translational Science 2015 meeting, Washington, DC.

  37. Inal C, Piperdi B, Keller SM, Halmos B, Stoopler M, Limaye SA, Levy BP, Schneider BJ, Kim M, Sides J, Perez-Soler R, Cheng H. Neoadjuvant erlotinib in stage III NSCLC patients (pts) with activating EGFR mutations (EVENT trial). 2015 ASCO meeting, Chicago, IL, May 29-June 2 2015.

  38. Cheng H, Inal C, Yang Y, Gucalp R, Haigentz M, Packer S, Zhu C, Wilson K, Perez-Soler R. EGFR mutation pattern in African American population in a community-based academic center. 2015 ASCO meeting, Chicago, IL, May 29-June 2 2015.

  39. Yang Y, Shum H, Haigentz M, Mariuma E, Suhrland M, Maleki S, Acevedo N, Gulko E, Farinhas J, Welch M. “Anti-Ri antibody associated paraneoplastic brainstem and cerebellar dysfunction as the presenting sign of small cell lung carcinoma."  American Academy of Neurology 67th Annual Meeting, April, 2015.

  40. Cheng H, Inal C, Yang Y, Gucalp RA, Haigentz M, Packer SH, Zhu C, Wilson K, Perez-Soler R. EGFR mutation pattern in African American population in a community-based academic center.   J Clin Oncol 33, 2015 (suppl; abstr 8069).

  41. Pendurti G, Shah UH, Swami U, Hou Y, Ghalib MH, Chaudhary I,  Polineni R, Klobocista M, Mukherjee P, Chuy JW, Kaubisch A, Rajdev L, Aparo S, Goel S. Developing a novel prognostic model to predict overall survival (OS) and 90 day mortality rate (90DM) for metastatic colorectal cancer (mCRC) patients in phase I trials. J Clin Oncol 33, 2015 (suppl; abstr e14618).

  42. Kaner JD, Assal A, Sridharan A, Polineni R, Shastri A, Elias H, Goel S, Janakiram M, Braunschweig I, Verma A. Analysis of a large single center cohort demonstrates poor prognosis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in HIV infected patients (pts). J Clin Oncol 33, 2015 (suppl; abstr e18077).

  43. Inal C, Piperdi B, Steven M. Keller, Halmosm B, Stoopler M, Limaye S, Levy BP, Schneider BJ, Kim M, Sides J, Perez-Soler R, Cheng H. Neoadjuvant erlotinib in stage III NSCLC patients (pts) with activating EGFR mutations (EVENT trial). J Clin Oncol 33, 2015 (suppl; abstr TPS7584).

  44. Yilmaz E,  Champa D, Di Cristofano A. Synergistic effect of combined PI3K and PLK1 inhibition in anaplastic thyroid carcinoma cells. J Clin Oncol 33, 2015 (suppl; abstr e22205).

  45. Boiles AR, Prasanna D, Shaker AB, Oswald M, Mason C, Keogh M, Lee A, Shapira I. Integrated analysis of miRNAs expression in breast cancer patients to detect genes deregulation involved in malignant transformation.  J Clin Oncol 33, 2015 (suppl; abstr e12560).

  46. Prasanna D, Shaker AB, Boiles AR, Oswald M, Mason C, Keogh M, Lee A, Shapira I. Implications of high expression of miR17-92 cluster in ovarian cancer (OvCa) tissue found in long term survivors.  J Clin Oncol 33, 2015 (suppl; abstr e12561).

  47. Shaker AB, Boiles AR, Prasanna D, Oswald M, Mason C, Keogh M, Lee A, Shapira I.. MiR expression in ovarian cancer (OvCa) and benign ovarian cystic masses (BOM) point to divergent molecular pathways of proliferation and metastasis. J Clin Oncol 33, 2015 (suppl; abstr e16557).

  48. Yilmaz E, Russo MA, Orlacchio A, Forde T, Di Cristofano A. MYC amplification and overexpression in metastatic anaplastic thyroid cancer dictates response to therapy. Poster Presentation at American Association for Cancer Research Annual Meeting (2015) Abs. 2023.
    • AACR Scholar In-training Award
    • First prize with oral presentation in New York Head and Neck Society Annual Proffered Paper Session Meeting?